Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biodesix has demonstrated the efficacy of pretreatment blood-based test, VeriStrat to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent) and erlotinib (Tarceva).
Subscribe to our email newsletter
VeriStrat is a serum proteomic for patients with advanced NSCLC, which identifies patients likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).
According to the data, patients who tested VeriStrat Good showed considerably longer progression free survival (PFS) and overall survival (OS) when treated with the combination therapy as compared to patients who tested VeriStrat Poor.
The VeriStrat test was applied to a subset of the patient population from a Phase I/II clinical trial of erlotinib plus sunitinib in RCC patients.
Of 46 patients, 37 were classified as either VeriStrat Good or VeriStrat Poor based on the VeriStrat algorithm developed for non-small cell lung cancer (NSCLC).